Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading Volume – Should You Buy?

Royalty Pharma plc (NASDAQ:RPRXGet Free Report) shares saw strong trading volume on Tuesday . 4,706,208 shares changed hands during trading, an increase of 13% from the previous session’s volume of 4,152,292 shares.The stock last traded at $31.69 and had previously closed at $31.72.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, Citigroup cut their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and an average target price of $41.67.

Read Our Latest Research Report on Royalty Pharma

Royalty Pharma Stock Down 1.1 %

The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm’s 50 day simple moving average is $27.13 and its two-hundred day simple moving average is $27.47. The firm has a market cap of $18.61 billion, a price-to-earnings ratio of 16.37 and a beta of 0.47.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a $0.22 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds have recently bought and sold shares of the company. Brooklyn Investment Group increased its holdings in Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the period. Allworth Financial LP grew its holdings in shares of Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 877 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 943 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Spire Wealth Management grew its holdings in shares of Royalty Pharma by 377.6% during the 4th quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,699 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.